Order results by:
| Issue | Title | |
| Vol 16, No 5 (2024) | Efficacy and safety of cladribine tablets in multiple sclerosis in real-world clinical practice | Abstract similar documents |
| A. N. Peshkin, S. V. Kotov, G. T. Toniya, M. V. Sutormin, A. F. Eltayoury | ||
| "... of cladribine was calculated based on the body weight. Results. The average frequency of exacerbations per year ..." | ||
| Vol 12, No 1S (2020): Спецвыпуск: рассеянный склероз | Experience with cladribine tablets for highly active multiple sclerosis in everyday clinical practice | Abstract similar documents |
| S. V. Petrov, O. V. Boyko, A. N. Boyko | ||
| "... Cladribine tablets are a new drug for the immune reconstitution therapy of highly active multiple ..." | ||
| Vol 14, No 1 (2022) | Experience with cladribine tablets for highly active multiple sclerosis in real clinical practice | Abstract similar documents |
| S. V. Petrov, O. V. Boyko, A. N. Boyko | ||
| "... Objective: to evaluate the efficacy and safety of cladribine tablets as a treatment for immune ..." | ||
| Vol 16, No 3 (2024) | Experience of cladribine tablets usage in the treatment of multiple sclerosis in the Multiple Sclerosis Centre of the Khanty-Mansi Autonomous Area — Yugra | Abstract similar documents |
| A. A. Sokolova, L. I. Anischenko, L. S. Zemlyanushin, E. A. Rubtsova | ||
| "... therapy with cladribine tablets with an average frequency of exacerbations of 1.2 (62 exacerbations in 48 ..." | ||
| Vol 12, No 3 (2020) | Recommendations for the use of cladribine tablets for the pathogenetic treatment of patients with highly active multiple sclerosis | Abstract similar documents |
| K. Z. Bakhtiyarova, A. N. Boyko, Ya. V. Vlasov, Z. A. Goncharova, M. V. Davydovskaya, M. N. Zakharova, N. A. Malkova, A. I. Nilov, S. A. Sivertseva, N. N. Spirin, N. A. Totolyan, F. A. Khabirov, M. V. Shumilina | ||
| "... participate in the clinical trials of cladribine tablets in MS, presents a consensus on the practical aspects ..." | ||
| Vol 16 (2024): (Suppl. 2) | Experience with the use of cladribine tablets in real-life clinical practice: independent analysis of data from 12 Russian clinical centres | Abstract similar documents |
| A. N. Boyko, V. M. Alifirova, D. V. Pashkovskaya, E. I. Kuchina, S. A. Sivertseva, E. L. Turova, Z. A. Goncharova, O. Yu. Rudenko, Yu. Yu. Pogrebnova, F. A. Khabirov, T. I. Khaibullin, N. N. Babicheva, N. L. Khoroshilova, O. V. Dzundza, O. A. Soldatova, A. N. Belova, G. Е. Sheiko, A. Е. Makarova, N. G. Glavinskaya | ||
| "... of cladribine tablets in daily practice on the course of MS over 3–4 year observational period after immune ..." | ||
| Vol 15 (2023): (Suppl. 1) | Prolonged observation after the use of cladribine in multiple sclerosis: efficacy and safety | Abstract similar documents |
| A. D. Kukushkina, A. N. Boyko | ||
| "... of advantages, including short treatment courses with long-term effects on immune mechanisms. Cladribine tablets ..." | ||
| Vol 12, No 5 (2020) | Recommendations for switching patients with highly active multiple sclerosis from other disease modifying drugs for multiple sclerosis to cladribine tablets | Abstract similar documents |
| N. A. Totolyan, V. M. Alifirova, K. Z. Bakhtiyarova, A. N. Boyko, Ya. V. Vlasov, Z. A. Goncharova, M. N. Zakharova, D. S. Kasatkin, S. V. Kotov, A. I. Nilov, S. A. Sivertseva, A. A. Sokolova, N. N. Spirin, F. A. Khabirov, D. Paradnika | ||
| "... a consensus on the practical aspects of switching patients with HAMS from other DMDMS to cladribine tablets ..." | ||
| Vol 16, No 1S (2024): Спецвыпуск: Головная боль | Gastric stasis in migraine and the efficacy of antimigraine drugs | Abstract similar documents |
| G. R. Tabeeva, A. A. Kharitonova | ||
| "... dispersible tablets, efficacy in relieving pain and accompanying symptoms, and ease of administration make ..." | ||
| Vol 15, No 2 (2023) | Optimization of migraine attacks relief | Abstract similar documents |
| G. R. Tabeeva, A. V. Amelin, L. R. Akhmadeeva, A. B. Danilov, O. B. Doronina, M. I. Koreshkina, N. V. Latysheva, E. G. Mendelevich, I. V. Sarvilina, A. V. Sergeev, K. V. Skorobogatykh, E. G. Filatova | ||
| "... tablets, oral dispersible forms, injections, nasal sprays, rectal suppositories). Rizatriptan in the form ..." | ||
| Vol 15, No 4 (2023) | Evaluation of pharmacokinetic parameters, safety and tolerability of single and multiple doses of Vespireit®: results of phase I clinical trial. | Abstract similar documents |
| O. D. Ostroumova, M. L. Maksimov, M. V. Zamergrad, V. A. Parfenov, E. K. Zaharova, A. L. Vladykin, A. A. Globenko, A. V. Kapashin, K. A. Ishchenko | ||
| "... buspirone), prolonged-release tablets, 15 mg (JSC “Valenta Pharm”, Russia), which is being developed ..." | ||
| Vol 16, No 5 (2024) | Experience of using Russian rizatriptan 10 mg tablets in routine clinical practice: results of a multicenter post-registration observational study “OPYT” | Abstract similar documents |
| G. R. Tabeeva, A. B. Danilov, M. I. Koreshkina, E. Z. Yakupov, A. V. Amelin, А. A. Artamonov | ||
| Vol 15, No 5 (2023) | Efficacy and safety of Vespireit® (buspirone) prolonged-release tablets (PR) 15 mg in the therapy of patients with functional dizziness: results of the double-blind, placebo-controlled, multicenter, randomized, phase 3 clinical trial | Abstract similar documents |
| M. V. Zamergrad, V. A. Parfenov, A. S. Agafina, N. V. Lyamina, M. M. Gavrik, L. R. Kuchumova, E. R. Barantsevich, V. S. Krasnov, A. A. Ivanova, A. L. Vladykin, K. А. Ishchenko | ||
| "... : to evaluate the efficacy and safety of Vespireit® (INN buspirone) prolonged-release tablets 15 mg2 (JSC ..." | ||
| Vol 14, No 5 (2022) | Current view on the diagnosis and treatment of neuromyelitis optica spectrum disorders exacerbations | Abstract similar documents |
| V. S. Krasnov, L. N. Prakhova, N. A. Totolyan | ||
| "... ) are formed as a result of exacerbations, which are often life-threatening. Timely diagnosis and treatment ..." | ||
| Vol 15, No 6 (2023) | NOVEMA® NIGHT (diphenhydramine + naproxen) in patients with pain and insomnia: results of a multicenter non-interventional observational study | Abstract similar documents |
| A. B. Danilov, A. A. Pilipovich, M. V. Pyastolova | ||
| "... of the combination of diphenhydramine + naproxen (NOVEMA® NIGHT) in patients with acute pain syndrome or exacerbation ..." | ||
| Vol 14, No 3 (2022) | Combined therapy for Alzheimer's disease | Abstract similar documents |
| V. V. Zakharov, A. V. Lokshina, N. V. Vakhnina | ||
| "... combination of these drugs in a single tablet once daily regimen has been shown to provide significant ..." | ||
| Vol 15, No 4 (2023) | Pharmacokinetic parameters, safety and drug-drug interactions of mirtazapine and tizanidine, combined in the new original drug Dorsumio® | Abstract similar documents |
| A. S. Goncharov, A. V. Grigoriev, A. A. Globenko, I. S. Goncharov, K. A. Muratov, D. V. Yaroshenko, A. A. Sidorova, A. V. Kapashin, O. V. Kovchan, A. I. Bashkatova, M. A. Pasko | ||
| "... + tizanidine, extended-release tablets, 15 mg + 6 mg, JSC Valenta Pharm, Russia) taken once by healthy ..." | ||
| Vol 15, No 3 (2023) | Clinical effectiveness and safety of prolonged release form of alimemazine in patients with generalized anxiety disorder | Abstract similar documents |
| Ju. E. Azimova, Yu. P. Sivolap, K. A. Ishchenko | ||
| "... The prolonged release tablets form of alimemazine is seen as a promising agent for the long-term ..." | ||
| Vol 4, No 4 (2012) | Citicoline for ischemic stroke: ICTUS trial | Abstract similar documents |
| Vladimir Anatolyevich Parfenov | ||
| "... as one 500-mg tablet every 12 hours during 6 weeks). The results of the trial confirmed the safety ..." | ||
| Vol 13, No 6 (2021) | Multicenter, randomized, double-blind study of the efficacy and safety of prolonged release tolperisone hydrochloride 450 mg (Mydocalm® Long, once daily) and tolperisone hydrochloride 150 mg (three times daily) for acute non-specific lower back pain | Abstract similar documents |
| V. A. Parfenov, E. I. Bogdanov, V. B. Laskov, N. S. Makarov, N. V. Pisova, E. A. Salina, Zh. Yu. Chefranova, L. V. Chichanovskaya | ||
| "... tablets of 150 mg (TH 150) to one tablet of PRTH 450. Objective: to evaluate the therapeutic efficacy ..." | ||
| Vol 4, No 2 (2012) | A change in the parameters of P300 evoked potentials in relation to the degree of exacerbation of pain syndrome | Abstract similar documents |
| A P Rachin, A A Averchenkova | ||
| Vol 2, No 4 (2010) | Pediatric Tenoten in therapy of childhood nocturnal enuresis | Abstract similar documents |
| G. M. Dzhanumova, A. V. Budkevich, L. B. Ivanov | ||
| "... ; Group 1) and fenibut (n = 18; Group 2). Tenoten (pediatric formulation) was given a sublingual tablet ..." | ||
| Vol 6, No 1 (2014) | The use of neurocytoprotectors to improve rehabilitation of patients after cerebrovascular accident | Abstract similar documents |
| V.V. Kovalchuk | ||
| "... received intravenous infusion of Thiocetam at a dose of 30 ml for 14 days, then 1 tablet TID for 1 month ..." | ||
| Vol 4, No 1 (2012) | Sustained-release pramipexole in the treatment of Parkinson’s disease | Abstract similar documents |
| Natalia Vladimirovna Fedorova | ||
| "... of a tablet. Both formulations contain the same active ingredient, have the similar profile of interacting ..." | ||
| Vol 12, No 6 (2020) | Nonsteroidal anti-inflammatory drugs, muscle relaxants, and B-group vitamins in the treatment of lumbar ischialgia | Abstract similar documents |
| V. A. Shirokov, A. V. Potaturko, N. L. Terekhov | ||
| "... 15-mg tablet daily for 14 days; Group 2 received IM meloxicam 15 mg daily for 3 days, followed by one ..." | ||
| Vol 14, No 5 (2022) | Safety of Mexidol® (ethylmethylhydroxypyridine succinate) in adult patients of different age groups | Abstract similar documents |
| E. A. Ushkalova, S. K. Zyryanov, O. I. Butranova | ||
| "... and intramuscular injection, 50 mg/ml (NPK PHARMASOFT, Russia) and Mexidol® FORTE 250 film-coated tablets, 250 mg ..." | ||
| Vol 6, No 3 (2014) | Current therapy for Parkinson's disease | Abstract similar documents |
| A. V. Obukhova | ||
| "... interaction profile, but differ in the tablet release rate of the active ingredient. The advantages ..." | ||
| Vol 10, No 1 (2018) | Treatment of vertigo in elderly patients with chronic cerebrovascular disease | Abstract similar documents |
| S. N. Duma | ||
| "... who took betahistine 48 mg/day, intravenous Mexidol® 5.0 ml for 10 days, then 375 mg tablets daily ..." | ||
| Vol 15, No 1 (2023) | New possibilities for the treatment of mild cognitive impairment and prevention of dementia in patients with cerebrovascular disease. Results of the PRIORITET Observation Program | Abstract similar documents |
| E. Y. Solovieva, P. R. Kamchatnov, L. B. Novikova, O. A. Kicherova, N. M. Khasanova | ||
| "... inclusive (mean age 63.6±8.8 years) with MCI and CVD, they were prescribed Prospecta, two tablets twice ..." | ||
| Vol 12, No 3 (2020) | Features of the pathogenesis, diagnosis, and treatment of panic attacks in young people | Abstract similar documents |
| M. L. Chukhlovina | ||
| "... ) as a 15-mg tablet thrice daily for 8 weeks; 2) 17 patients who were prescribed only standard therapy ..." | ||
| Vol 13, No 1 (2021) | Evaluation of the efficacy and tolerability of naftidrofuryl in the therapy of chronic cerebral ischemia | Abstract similar documents |
| M. N. Dadasheva, I. A. Zolotovskaya, R. V. Gorenkov, K. N. Dadasheva, D. I. Lebedeva | ||
| "... and received its full cycle. The patients were prescribed naftidrofuryl at a dose of 100 mg (2 tablets) thrice ..." | ||
| Vol 12, No 2 (2020) | Efficacy of tolperisone versus meloxicam in the treatment of nonspecific acute neck pain | Abstract similar documents |
| K. V. Skorobogatykh, Yu. E. Azimova | ||
| "... and 18 formed Group 2. Group 1 was prescribed tolperisone (Calmirex) as tablets: 150 mg/day on day 1, 300 ..." | ||
| Vol 16, No 4 (2024) | Treatment of post-traumatic cognitive disorders and asthenia: results of an observational study | Abstract similar documents |
| P. R. Kamchatnov, O. Yu. Tsarapkina, N. G. Malyukova, A. V. Miretskaya, E. F. Danshina, L. A. Skipetrova, R. A. Cheremin | ||
| "... 1 tablet of Prospekta twice daily for 4 weeks. Cognitive functions, particularly the speed ..." | ||
| Vol 1, No 1 (2009) | TENOTEN IN COMPLEX THERAPY FOR CEREBROVASCULAR INSUFFICIENCY IN ELDERLY PATIENTS | Abstract similar documents |
| L. D. Serova | ||
| "... of 20 patients. During 28 days, the study group patients received tenoten as a tablet thrice daily ..." | ||
| Vol 14, No 2 (2022) | Possibilities nootropic drugs in non-demented patients with vascular cognitive disorders | Abstract similar documents |
| M. N. Dadasheva, R. V. Gorenkov, V. A. Kruglov, K. N. Dadasheva, D. I. Lebedeva | ||
| "... recieved omberacetam 10 mg 2 times per day, the 2nd group – piracetam/cinnarizine 400/25 mg (1 tablet) 3 ..." | ||
| Vol 13, No 4 (2021) | Fatigue and cognitive impairment in post-COVID syndrome: possible treatment approaches | Abstract similar documents |
| A. N. Bogolepova, N. A. Osinovskaya, E. A. Kovalenko, E. V. Makhnovich | ||
| "... tablet three times per day). Patients with CI (mean MoCA score ≤25 points; n=50) were prescribed ..." | ||
| Vol 16 (2024): (Suppl. 2) | Optimization of therapy in secondary progressive multiple sclerosis | Abstract similar documents |
| A. N. Boyko, S. K. Zyryanov, Ya. V. Vlasov | ||
| "... sclerosis (SPMS). The only drug that has proven its effectiveness in all types of SPMS (with exacerbations ..." | ||
| Vol 11, No 4 (2019) | Recommendations from the Expert Meeting «Secondary progressive multiple sclerosis: unresolved issues and prospects» | Abstract similar documents |
| N. V. Khachanova, A. N. Boyko, K. Z. Bakhtiyarova, Ya. V. Vlasov, E. P. Evdoshenko, S. A. Sivertseva, T. E. Schmidt, M. V. Shumilina | ||
| "... progression can be recorded, is stated to be 3 months. The exacerbation-unaffected disability progression ..." | ||
| Vol 16 (2024): (Suppl. 2) | Sampeginterferon beta-1a in clinical practice | Abstract similar documents |
| I. A. Sokolova, O. S. Kornakova, E. V. Sokolova | ||
| "... initially received glatiramer acetate as DMT, which led to exacerbations and an increase in neurological ..." | ||
| Vol 11, No 1 (2019) | Experience with anti-B-cell therapy in the pathogenetic treatment of multiple sclerosis | Abstract PDF (Eng) similar documents |
| O. V. Boyko, S. V. Petrov, N. Yu. Lashch, M. R. Guseva, A. N. Boyko | ||
| "... MS (PPMS), secondary progressive MS (SPMS) and exacerbations, and highly active MS. Objective ..." | ||
| Vol 16 (2024): (Suppl. 2) | Neuromyelitis optica spectrum disorders in children | Abstract similar documents |
| N. F. Akhmetgaleeva, T. O. Simaniv, E. M. Yausheva, Yа. A. Saitova, O. V. Lyutov, M. A. Kutlubaev, K. Z. Bakhtiyarova | ||
| "... is paid to the pathogenetic treatment of exacerbations and targeted therapy to prevent exacerbations ..." | ||
| Vol 11, No 2 (2019) | Tobacco smoking dependence in patients with depressive spectrum mental disorders: clinical, pathogenetic, and therapeutic aspects | Abstract similar documents |
| O. I. Speranskaya, S. A. Trushchelev, Z. I. Storozheva | ||
| "... a gradual reduction in tobacco withdrawal syndrome and to prevent an exacerbation of comorbid depression. ..." | ||
| Vol 10, No 1 (2018) | New drugs for anti-B-cell therapy of multiple sclerosis | Abstract similar documents |
| A. N. Boyko, N. Yu. Lashch, M. E. Guseva | ||
| "... that this drug is effective in treating both MS with exacerbations and primary progressive MS. Currently ..." | ||
| Vol 9, No 2 (2017) | Chronic cerebral ischemia, neuroplasticity, possibilities of therapy | Abstract similar documents |
| E. I. Chukanova, A. S. Chukanova | ||
| "... , progression, and risk of exacerbations in patients with chronic cerebral ischemia. ..." | ||
| Vol 2, No 4 (2010) | Osteoarthrosis or osteoarthritis? The name of the disease through the eyes of a practitioner | Abstract similar documents |
| N. A. Khitrov | ||
| "... characteristics of synovitis in OA. The author describes anti-inflammatory therapy for knee OA in an exacerbation ..." | ||
| Vol 3, No 2 (2011) | Medical psychosomatics. Apropros of one date | Abstract similar documents |
| M. Yu. Drobizhev, A. A. Ovchinnikov, K. Yu. Retyunskiy, S. V. Kikta | ||
| "... disorder and a somatic disease affect each other (provoke an exacerbation, aggravate their course ..." | ||
| Vol 10, No 2 (2018) | The clinical and psychological features of mental development in children with opsoclonus-myoclonus syndrome | Abstract similar documents |
| N. S. Burlakova, Yu. V. Mikadze, Yu. N. Fedorova, R. Ts. Bembeeva, E. S. Ilyina, N. N. Zavadenko | ||
| "... with opsoclonus-myoclonus syndrome (OMS) in relation to the number of exacerbations. Patients and methods ..." | ||
| Vol 2, No 2 (2010) | Vestibular vertigo in emergency neurology and cervical osteochondrosis | Abstract similar documents |
| T. S. Barykova, E. V. Fastakovskaya | ||
| "... of vertebral artery irritation during an exacerbation of cervical osteochondrosis. The «cerebral» level ..." | ||
| Vol 14, No 6 (2022) | On the use of chondroitin sulfate, glucosamine sulfate and undenatured type II collagen for back and limb pain and osteoarthritis | Abstract similar documents |
| O. A. Gromova, I. Y. Torshin, A. M. Lila | ||
| "... tissue of the joint, which affects the nerve terminals and leads to an exacerbation of pain symptoms ..." | ||
| Vol 4, No 3 (2012) | Prevention and therapy of psychopathological disorders in patients with cardiovascular diseases | Abstract similar documents |
| Vladimir Ernstovich Medvedev | ||
| "... of psychotropic drugs and psychotherapy are shown to result in a reduction in the incidence of exacerbations ..." | ||
| Vol 15 (2023): (Suppl. 1) | Diagnostic criteria and treatment of neuromyelitis optica spectrum disorders (NMOSD) | Abstract similar documents |
| T. O. Simaniv, K. Z. Bakhtiyarova, A. N. Belova, Z. A. Goncharova, S. A. Sivertseva, N. N. Spirin, N. A. Totolyan, T. N. Trushnikova, E. L. Turova, T. I. Khaibullin, M. A. Sherman, A. N. Boyko | ||
| "... of the central nervous system. They are characterized by periodic, unpredictable exacerbations that lead ..." | ||
| Vol 16, No 6 (2024) | Neuromyelitis optica spectrum disorders, terminology and therapeutic issues: amended consensus opinion | Abstract similar documents |
| V. S. Krasnov, Yu. V. Vlasov, E. P. Evdoshenko, D. S. Korobko, M. D. Matson, A. I. Nilov, A. A. Sokolova, N. A. Totolian, N. V Khachanova, M. V. Shumilina, M. V. Davydovskaya | ||
| "... for prescribing medications that prevent exacerbations in patients with NMOSD with AQP4-IgG aged 18 years ..." | ||
| Vol 14, No 1S (2022): Спецвыпуск: рассеянный склероз | Results of a study of the quality of life in patients with highly active multiple sclerosis in Russia | Abstract similar documents |
| A. N. Boiko, K. Z. Bakhtiyarova, M. A. Sherman, Z. A. Goncharova, I. V. Smagina, T. I. Khaibullin, N. N. Babicheva, N. N. Spirina, I. A. Yampolskaya-Gosteva, I. A. Sokolova, I. V. Greshnova, V. E. Nikitenkova, I. G. Lukashevich, A. V. Inzhinova, N. A. Malkova, D. S. Korobko, O. V. Boyko, I. S. Lozovskaya | ||
| "... exacerbations without taking specific pathogenetic therapy or one exacerbation during taking MS disease ..." | ||
| Vol 7, No 1S (2015): Special issue "Epilepsy" | Epilepsy in patients with multiple sclerosis: specific features of diagnosis and therapy | Abstract similar documents |
| Yu. A. Belova, T. I. Yaukushina, I. G. Rudakova, S. V. Kotov | ||
| "... .59 years) were observed to have ES. The annual MS exacerbation rate was 1.2±1.19. Two MS patients were ..." | ||
| Vol 16, No 4 (2024) | Functional dizziness: from diagnostic criteria to clinical profiles and therapy. Expert consensus | Abstract similar documents |
| M. V. Zamergrad, V. A. Parfenov, O. D. Ostroumova, A. L. Guseva, O. V. Zaytseva, Yu. P. Sivolap, I. V. Kukes, V. A. Voronov | ||
| "... psychotherapy and vestibular rehabilitation methods. The use of buspirone prolonged-release tablets (Vespirate ..." | ||
| Vol 14, No 6 (2022) | Consensus opinion on the management of patients with neuromyelitis optica spectrum diseases: issues of terminology and therapy | Abstract similar documents |
| V. S. Krasnov, K. Z. Bakhtiyarova, E. P. Evdoshenko, D. S. Korobko, T. O. Simaniv, N. A. Totolyan, N. V. Khachanova, M. V. Shumilina, M. V. Davydovskaya | ||
| "... a therapeutic algorithm to prevent exacerbations in patients with NMOSD with serum IgG antibodies to aquaporin-4 ..." | ||
| Vol 12, No 6 (2020) | COVID-19 and mental health: challenges and first conclusions | Abstract similar documents |
| V. E. Medvedev, O. A. Dogotar | ||
| "... in the foci of infection. The manifestation or exacerbation of mental illness in turn contributes ..." | ||
| Vol 13, No 1 (2021) | Depression during the COVID-19 pandemic (analysis of clinical cases) | Abstract similar documents |
| I. Yu. Dorozhenok | ||
| "... . The multifactorial stressor effect of the COVID-19 pandemic has provoked an exacerbation of depression in a male ..." | ||
| Vol 9, No 4 (2017) | Neurological complications of alcoholism | Abstract similar documents |
| I. I. Nikiforov, M. M. Rakitin, A. G. Merkin, P. V. Aronov, G. P. Kostyuk, D. V. Savelyev, R. N. Isaev, A. V. Kazantsev, V. A. Priyatel, I. A. Nikiforov | ||
| "... pathological craving for alcohol. Neurological pathology in turn occurs with frequent exacerbations ..." | ||
| Vol 3, No 3 (2011) | Analysis of reasons for failed surgery treatment in patients with back pain | Abstract similar documents |
| M. S. Kokina, E. G. Filatova | ||
| "... exacerbation, the frequency of admissions, the presence of radicular syndrome, the size of intervertebral ..." | ||
| Vol 15, No 6 (2023) | Russian-Belarusian Expert Council “New opportunities in the treatment of patients with multiple sclerosis” (October 1, 2023). Main conclusions of the first meeting | Abstract similar documents |
| A. N. Boyko, V. V. Vashchilin, O. V. Boyko, A. G. Bunyak, D. S. Kasatkin, D. S. Korobko, S. I. Kulikova, N. V. Mazgo, N. V. Makovskaya, S. A. Sivertseva, I. V. Smagina, T. N. Chernukha | ||
| "... progressive (with exacerbations) MS. The experts emphasized how promising the use of these drugs ..." | ||
| Vol 15 (2023): (Suppl. 1) | Neuromyelitis optic spectrum disorders (NMOSD): from pathogenesis to targeted therapy | Abstract similar documents |
| P. A. Zaitseva, A. N. Boyko | ||
| "... of pathogenetic treatment of NMOSD are discussed, which has two main directions: treatment of exacerbations ..." | ||
| Vol 12, No 1 (2020) | Association of BAFF gene polymorphisms with multiple sclerosis progression | Abstract PDF (Eng) similar documents |
| I. V. Smagina, S. A. Elchaninova, A. S. Palashchenko | ||
| "... 1224141, rs9514827) with the progression rate and frequency of MS exacerbations. Patients and methods ..." | ||
| Vol 15, No 4 (2023) | Psychosomatic correlations in mentally ill and mentally healthy women with infertility | Abstract similar documents |
| A. O. Nikolaevskaya, N. A. Tyuvina, V. D. Morozova, E. P. Kesler | ||
| "... during the period of exacerbation of the disease, insufficient emotional response to menarche (p<0 ..." | ||
| Vol 16 (2024): (Suppl. 2) | High-dose immunosuppressive therapy followed by haematopoietic stem cell transplantation as a method for the treatment of refractory forms of neuromyelitis optica spectrum disorder in children | Abstract similar documents |
| N. N. Bronina, O. V. Bykova, G. O. Bronin, A. E. Kessel, G. Z. Seregin, K. I. Kirgizov, A. Yu. Polushin, T. T. Batysheva | ||
| "... NMOSD is presented. A 10-year-old boy had two exacerbations within four months against the background ..." | ||
| Vol 16 (2024): (Suppl. 2) | Results of tele-rehabilitation in patients with multiple sclerosis during 2020–2021 COVID-19 pandemic | Abstract similar documents |
| S. A. Sivertseva, K. S. Anfilofeva, A. V. Zotova, V. D. Chukreev, A. Yu. Belkina, L. I. Volkova, M. E. Guseva, A. N. Boyko | ||
| "... .13 (p<0.05). No exacerbations of the disease were recorded during the TeleRBT period. Conclusion ..." | ||
| Vol 16 (2024): (Suppl. 2) | Analysis of the experience with once-weekly intramuscular administration of interferon beta-1a in the Russian population of patients with relapsing-remitting multiple sclerosis | Abstract similar documents |
| F. A. Khabirov, E. V. Granatov, A. Ya. Dykhanov, T. I. Khaibullin | ||
| "... administration, which has moderate efficacy in reducing clinical exacerbations of multiple sclerosis (MS), which ..." | ||
| Vol 12, No 1 (2020) | Comparative efficacy and tolerance of centrally acting muscle relaxants in elderly patients with nonspecific musculoskeletal pain | Abstract similar documents |
| R. V. Gorenkov, M. N. Dadasheva, I. A. Zolotovskaya, V. A. Kruglov | ||
| "... took a muscle relaxant as tablets for 15 days: Group 1 received the Russian drug tolperisone (calmyrex ..." | ||
| Vol 14, No 3 (2022) | Acute and long-term neurological disorders in patients with coronavirus infection | Abstract PDF (Eng) similar documents |
| V. A. Parfenov, A. A. Kulesh | ||
| "... or exacerbation of a comorbid disease, including primary headache, musculoskeletal pain in the neck and back ..." | ||
| Vol 12, No 5 (2020) | B vitamins and nonsteroidal anti-inflammatory drugs: the efficacy of the combination for nonspecific back pain | Abstract similar documents |
| V. A. Golovacheva, A. A. Golovacheva | ||
| "... over NSAID monotherapy in the treatment of acute NBS and exacerbations of chronic NBS. The addition ..." | ||
| 1 - 70 of 91 Items | 1 2 > >> | |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
